Mitsubishi Chemical Holdings, a Japanese chemicals company, reported 17.7 per cent decrease in sales to ¥1504.8 billion (Japanese Yen) during the first half (H1) FY21 ended on September 30, 2020 compared to sales of ¥1,827.6 billion in same period prior fiscal. Net loss for the period was ¥39.9 billion in compared to net income of ¥101.7 billion in H1 FY20.
Mitsubishi Chemical Holdings, a Japanese chemicals company, reported 17.7 per cent decrease in sales to ¥1504.8 billion (Japanese Yen) during the first half (H1) FY21 ended on September 30, 2020 compared to sales of ¥1,827.6 billion in same period prior fiscal. Net loss for the period was ¥39.9 billion in compared to net income of ¥101.7 billion in H1 FY20.#
Company’s gross profit was ¥414.0 billion (¥516.3 billion). Operating loss for the first six months was ¥28.1 billion compared to operating income of ¥130.5 billion in H1 FY20. Loss before taxes was ¥36.8 billion (H1 FY20: profit ¥122.4 billion).
Mitsubishi Chemical Holdings, a Japanese chemicals company, reported 17.7 per cent decrease in sales to ¥1504.8 billion (Japanese Yen) during the first half (H1) FY21 ended on September 30, 2020 compared to sales of ¥1,827.6 billion in same period prior fiscal. Net loss for the period was ¥39.9 billion in compared to net income of ¥101.7 billion in H1 FY20.#
Sales of performance products dropped to ¥473.6 billion (¥566.7 billion) amidst lower overall sales volumes for automobiles, including for performance polymers in advanced polymers. Sales of chemicals segment slipped to ¥381.0 billion (¥557.0 billion). Industrial gases segment sales was ¥381.4 billion (¥419.4 million).
Mitsubishi Chemical Holdings, a Japanese chemicals company, reported 17.7 per cent decrease in sales to ¥1504.8 billion (Japanese Yen) during the first half (H1) FY21 ended on September 30, 2020 compared to sales of ¥1,827.6 billion in same period prior fiscal. Net loss for the period was ¥39.9 billion in compared to net income of ¥101.7 billion in H1 FY20.#
However, healthcare segment was not much hindered with sales of ¥194.0 billion (¥195.5 billion) attributable to higher sales volumes primarily in domestic priority products, offset by lower domestic sales prices for pharmaceuticals owing to National Health Insurance drug price revisions and other factors.
Fibre2Fashion News Desk (JL)
.jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "UBM China (Shanghai)")
-Ltd..jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Thermore (Far East) Ltd.")
